Exosomal Transfer of lncRNA H19 Promotes Erlotinib Resistance in Non-Small Cell Lung Cancer via miR-615-3p/ATG7 Axis.
ATG7
erlotinib resistance
exosome
lncRNA H19
miR-615-3p
non-small cell lung cancer
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
12
2019
accepted:
28
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Drug resistance restrains the effect of drug therapy in non-small cell lung cancer (NSCLC). However, the mechanism of the acquisition of drug resistance remains largely unknown. This study aims to investigate the effect of exosomal lncRNA H19 on erlotinib resistance in NSCLC and the underlying mechanism. HCC827 and A549 cells were continuously grafted into erlotinib-containing culture medium to establish erlotinib-resistant cell lines. The expression of H19 and miR-615-3p was detected by qRT-PCR. The protein levels of MMP2, MMP9, CD9, CD63 and ATG7 were measured by Western blot. Cell viability and proliferation were determined by Cell Counting Kit-8 (CCK-8) and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay, respectively. Migration and invasion were assessed by transwell assay. Xenograft tumor models were used to investigate the effect of H19 on erlotinib resistance in vivo. Online software and dual-luciferase reporter assay were used to predicate the downstream targets and confirm the targeted relationships. H19 was upregulated in erlotinib-resistant cells, and knockdown of H19 inhibited cell proliferation, migration and invasion in erlotinib-resistant cells. Extracellular H19 can be packaged into exosomes. Exosomes containing H19 induced erlotinib resistance of sensitive cells, while knockdown of H19 abolished this effect. miR-615-3p was a target of H19 and can bind to ATG7. Exosomal H19 affected erlotinib resistance of erlotinib-resistant NSCLC cells via targeting miR-615-3p to regulate ATG7 expression. In addition, the serum exosomal H19 was upregulated in patients with erlotinib resistance. Furthermore, downregulated H19 decreased the resistance of tumor cells to erlotinib in vivo. Our study demonstrated that exosomal H19 facilitated erlotinib resistance in NSCLC via miR-615-3p/ATG7 axis, which might provide a potential target for the diagnosis and treatment of NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Drug resistance restrains the effect of drug therapy in non-small cell lung cancer (NSCLC). However, the mechanism of the acquisition of drug resistance remains largely unknown. This study aims to investigate the effect of exosomal lncRNA H19 on erlotinib resistance in NSCLC and the underlying mechanism.
METHODS
METHODS
HCC827 and A549 cells were continuously grafted into erlotinib-containing culture medium to establish erlotinib-resistant cell lines. The expression of H19 and miR-615-3p was detected by qRT-PCR. The protein levels of MMP2, MMP9, CD9, CD63 and ATG7 were measured by Western blot. Cell viability and proliferation were determined by Cell Counting Kit-8 (CCK-8) and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay, respectively. Migration and invasion were assessed by transwell assay. Xenograft tumor models were used to investigate the effect of H19 on erlotinib resistance in vivo. Online software and dual-luciferase reporter assay were used to predicate the downstream targets and confirm the targeted relationships.
RESULTS
RESULTS
H19 was upregulated in erlotinib-resistant cells, and knockdown of H19 inhibited cell proliferation, migration and invasion in erlotinib-resistant cells. Extracellular H19 can be packaged into exosomes. Exosomes containing H19 induced erlotinib resistance of sensitive cells, while knockdown of H19 abolished this effect. miR-615-3p was a target of H19 and can bind to ATG7. Exosomal H19 affected erlotinib resistance of erlotinib-resistant NSCLC cells via targeting miR-615-3p to regulate ATG7 expression. In addition, the serum exosomal H19 was upregulated in patients with erlotinib resistance. Furthermore, downregulated H19 decreased the resistance of tumor cells to erlotinib in vivo.
CONCLUSION
CONCLUSIONS
Our study demonstrated that exosomal H19 facilitated erlotinib resistance in NSCLC via miR-615-3p/ATG7 axis, which might provide a potential target for the diagnosis and treatment of NSCLC.
Identifiants
pubmed: 32606925
doi: 10.2147/CMAR.S241095
pii: 241095
pmc: PMC7294568
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4283-4297Informations de copyright
© 2020 Pan and Zhou.
Déclaration de conflit d'intérêts
The authors declare that they have no financial conflicts of interest.
Références
EMBO J. 2015 Apr 1;34(7):856-80
pubmed: 25712477
Pathol Res Pract. 2019 Nov;215(11):152638
pubmed: 31551175
Biochem Biophys Res Commun. 2018 May 15;499(3):719-726
pubmed: 29605294
Annu Rev Cell Dev Biol. 2011;27:107-32
pubmed: 21801009
Front Genet. 2019 Jul 26;10:688
pubmed: 31402930
Cell Death Dis. 2019 Jun 3;10(6):429
pubmed: 31160576
Biomed Pharmacother. 2018 May;101:406-413
pubmed: 29501762
Oncol Rep. 2018 Dec;40(6):3438-3446
pubmed: 30542738
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Drug Discov. 2013 May;12(5):347-57
pubmed: 23584393
Mol Med Rep. 2019 Oct;20(4):3583-3596
pubmed: 31432188
Oncol Res. 2019 Feb 5;27(2):269-279
pubmed: 29562959
Cancer Biol Ther. 2013 Jul;14(7):574-86
pubmed: 23792642
FEBS J. 2008 Oct;275(20):4929-44
pubmed: 18754771
Cancer Lett. 2019 Sep 10;459:122-134
pubmed: 31173853
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
J Cell Biochem. 2020 Jan;121(1):779-787
pubmed: 31452243
Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):182-7
pubmed: 26677873
Theranostics. 2018 Jun 24;8(14):3932-3948
pubmed: 30083271
J Cell Physiol. 2019 Nov;234(11):20721-20727
pubmed: 31032916
Biomed Pharmacother. 2018 Dec;108:316-324
pubmed: 30227324
Onco Targets Ther. 2019 Jan 09;12:495-508
pubmed: 30666128
Biomed Res Int. 2019 Mar 19;2019:9056458
pubmed: 31016202
Clin Cancer Res. 2017 Sep 1;23(17):5311-5319
pubmed: 28606918
Oncogene. 2012 Feb 23;31(8):939-53
pubmed: 21765470
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Med Sci Monit. 2018 Dec 21;24:9307-9316
pubmed: 30576305
Autophagy. 2011 May;7(5):509-24
pubmed: 21325880
Int J Oncol. 2019 Jan;54(1):339-347
pubmed: 30387831
Onco Targets Ther. 2016 Aug 11;9:4975-81
pubmed: 27563251
Oncogene. 2020 Jan;39(5):953-974
pubmed: 31601996
J Zhejiang Univ Sci B. 2019 Jun;20(6):488-495
pubmed: 31090274
Mol Med Rep. 2019 Dec;20(6):5272-5278
pubmed: 31638208
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
J Exp Clin Cancer Res. 2019 Apr 16;38(1):166
pubmed: 30992025
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
Drug Discov Today. 2019 Oct;24(10):2058-2067
pubmed: 31228614
Cell Death Dis. 2013 Oct 10;4:e838
pubmed: 24113172
J Clin Invest. 2020 Jan 2;130(1):404-421
pubmed: 31593555
Am J Pathol. 2019 Dec;189(12):2377-2388
pubmed: 31539518